Adult vaccination coverage in the United States: A database analysis and literature review of improvement strategies.

Amanda L Eiden, Louise Hartley, Diana Garbinsky, Cassondra Saande, Jon Russo, Meghan Hufstader Gabriel, Mark Price, Alexandra Bhatti
Author Information
  1. Amanda L Eiden: Merck & Co., Inc., Rahway, NJ, USA. ORCID
  2. Louise Hartley: RTI Health Solutions, Didsbury, Manchester, UK.
  3. Diana Garbinsky: RTI Health Solutions, Research Triangle Park, North Carolina, USA.
  4. Cassondra Saande: RTI Health Solutions, Research Triangle Park, North Carolina, USA.
  5. Jon Russo: RTI Health Solutions, Research Triangle Park, North Carolina, USA.
  6. Meghan Hufstader Gabriel: RTI Health Solutions, Research Triangle Park, North Carolina, USA.
  7. Mark Price: RTI Health Solutions, Research Triangle Park, North Carolina, USA.
  8. Alexandra Bhatti: Merck & Co., Inc., Rahway, NJ, USA.

Abstract

Despite vaccines being instrumental in reducing vaccine-preventable disease, adult vaccination rates in the United States (US) are below optimal levels. To better understand factors affecting vaccination rates, we analyzed trends in adult vaccination coverage using data from the Behavioral Risk Factor Surveillance System (BRFSS) and conducted a targeted literature review (TLR) on interventions to improve adult vaccination rates in the US. Both the BRFSS analysis and the TLR focused on influenza; pneumococcal disease; tetanus and diphtheria or tetanus, diphtheria, and acellular pertussis; herpes zoster; and human papillomavirus vaccination for US adults aged 18-64���years. The TLR additionally included hepatitis A and hepatitis B vaccination. Vaccination coverage rates (VCRs) and changes in VCRs were calculated using the 2011-2019 BRFSS survey data. For the TLR, the MEDLINE and MEDLINE In-Process databases were searched for articles on vaccination interventions published between January 2015 and June 2021. The BRFSS analysis showed that changes in VCRs were generally modest and positive for most states over the study period. The TLR included 32 articles that met the eligibility criteria; intervention strategies that improved adult vaccination outcomes incorporated an educational component, vaccination reminders or reinforcement at the point of care, or authorized non-clinician members of the healthcare team to vaccinate. Furthermore, interventions combining more than one approach appeared to enhance effectiveness. The strategies identified in this TLR will be valuable for policymakers and stakeholders to inform the development and implementation of evidence-based policies and practices to improve adult vaccination coverage.

Keywords

References

  1. BMC Health Serv Res. 2017 Jul 21;17(1):503 [PMID: 28732518]
  2. MMWR Surveill Summ. 2021 May 14;70(3):1-26 [PMID: 33983910]
  3. Vaccine. 2019 Jan 3;37(1):195-201 [PMID: 29958736]
  4. BMC Health Serv Res. 2019 Jul 10;19(1):474 [PMID: 31291959]
  5. Expert Rev Vaccines. 2023 Jan-Dec;22(1):481-494 [PMID: 37218717]
  6. Cancer Med. 2020 Feb;9(4):1553-1561 [PMID: 31869530]
  7. Vaccine. 2018 Feb 1;36(6):890-898 [PMID: 29329685]
  8. Nat Rev Immunol. 2021 Feb;21(2):83-100 [PMID: 33353987]
  9. Health Serv Res. 2017 Dec;52 Suppl 2:2307-2330 [PMID: 29130266]
  10. AIDS Res Hum Retroviruses. 2018 Jul;34(7):603-606 [PMID: 29661022]
  11. Pharmacoecon Open. 2021 Sep;5(3):411-423 [PMID: 33860921]
  12. Vaccine. 2015 Sep 11;33(38):4983-7 [PMID: 26192356]
  13. Ann Intern Med. 2022 Mar;175(3):432-443 [PMID: 35175828]
  14. Am J Infect Control. 2020 Mar;48(3):290-296 [PMID: 31630922]
  15. Hum Vaccin Immunother. 2015;11(9):2158-66 [PMID: 26091249]
  16. JAMA Intern Med. 2020 Jul 1;180(7):962-970 [PMID: 32421168]
  17. Influenza Other Respir Viruses. 2018 Sep;12(5):605-612 [PMID: 29681127]
  18. Front Microbiol. 2020 Jul 14;11:1526 [PMID: 32760367]
  19. MMWR Morb Mortal Wkly Rep. 2022 Apr 01;71(13):477-483 [PMID: 35358162]
  20. Vaccine. 2015 Jul 9;33(30):3571-9 [PMID: 26044495]
  21. Heart Lung. 2020 May - Jun;49(3):233-237 [PMID: 31982176]
  22. J Community Health. 2018 Apr;43(2):297-303 [PMID: 28852915]
  23. N C Med J. 2021 Mar-Apr;82(2):126-129 [PMID: 33649129]
  24. J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):182-6 [PMID: 25615903]
  25. Popul Health Manag. 2018 Feb;21(1):55-62 [PMID: 28609228]
  26. J Nurs Care Qual. 2015 Jul-Sep;30(3):205-11 [PMID: 25565463]
  27. MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31 [PMID: 25144544]
  28. Am J Infect Control. 2015 Mar 1;43(3):228-33 [PMID: 25728148]
  29. MMWR Recomm Rep. 2020 Jul 03;69(5):1-38 [PMID: 32614811]
  30. Hum Vaccin Immunother. 2016 Dec;12(12):3146-3159 [PMID: 27715409]
  31. Hum Vaccin Immunother. 2018 Feb 1;14(2):430-441 [PMID: 29194019]
  32. J Cancer Educ. 2017 Dec;32(4):871-877 [PMID: 27055536]
  33. BMC Fam Pract. 2020 Feb 29;21(1):46 [PMID: 32113475]
  34. P T. 2016 Aug;41(8):492-506 [PMID: 27504066]
  35. Vaccine. 2015 May 21;33(22):2521-3 [PMID: 25850021]
  36. J Rheumatol. 2018 Aug;45(9):1220-1228 [PMID: 29764963]
  37. Int J Clin Pharm. 2021 Oct;43(5):1163-1172 [PMID: 34047881]
  38. Vaccine. 2017 Apr 25;35(18):2390-2395 [PMID: 28351733]
  39. Popul Health Manag. 2020 Feb;23(1):29-37 [PMID: 31184967]
  40. J Am Pharm Assoc (2003). 2018 Sep - Oct;58(5):505-514.e2 [PMID: 30076098]
  41. AIDS Care. 2018 Feb;30(2):146-149 [PMID: 29052434]
  42. Ann Intern Med. 2018 Oct 2;169(7):467-473 [PMID: 30178033]
  43. J Rheumatol. 2017 Jan;44(1):11-17 [PMID: 28042124]
  44. MMWR Surveill Summ. 2017 May 05;66(11):1-28 [PMID: 28472027]
  45. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702 [PMID: 31415491]
  46. Clin Ther. 2017 Aug;39(8):1563-1580.e17 [PMID: 28781217]
  47. J Rheumatol. 2016 Jun;43(6):1030-7 [PMID: 27084914]
  48. Vaccine. 2019 Jan 21;37(4):631-636 [PMID: 30563788]
  49. Vaccine. 2016 Jun 24;34(30):3463-8 [PMID: 27219340]
  50. J Healthc Qual. 2020 May/Jun;42(3):166-174 [PMID: 31385855]
  51. Vaccine. 2016 Sep 22;34(41):5026-5033 [PMID: 27576073]

MeSH Term

Humans
United States
Vaccination Coverage
Adult
Young Adult
Middle Aged
Adolescent
Behavioral Risk Factor Surveillance System
Vaccination
Female
Male
Immunization Programs
Databases, Factual
Influenza Vaccines
Vaccine-Preventable Diseases

Chemicals

Influenza Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccinationTLRadultratescoverageBRFSSUSinterventionsanalysisVCRsstrategiesdiseaseUnitedusingdataliteraturereviewimprovetetanusdiphtheriaincludedhepatitischangesMEDLINEarticlesAdultDespitevaccinesinstrumentalreducingvaccine-preventableStatesoptimallevelsbetterunderstandfactorsaffectinganalyzedtrendsBehavioralRiskFactorSurveillanceSystemconductedtargetedfocusedinfluenzapneumococcalacellularpertussisherpeszosterhumanpapillomavirusadultsaged18-64���yearsadditionallyBVaccinationcalculated2011-2019surveyIn-ProcessdatabasessearchedpublishedJanuary2015June2021showedgenerallymodestpositivestatesstudyperiod32meteligibilitycriteriainterventionimprovedoutcomesincorporatededucationalcomponentremindersreinforcementpointcareauthorizednon-clinicianmembershealthcareteamvaccinateFurthermorecombiningoneapproachappearedenhanceeffectivenessidentifiedwillvaluablepolicymakersstakeholdersinformdevelopmentimplementationevidence-basedpoliciespracticesStates:databaseimprovementhealthpolicyimmunizationprogramsvaccinations

Similar Articles

Cited By